• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    MannKind Corp. (MNKD)

    1.35 Down 0.09(6.25%) Apr 29, 4:00PM EDT
    |After Hours : 1.35 0.00 (0.00%) Apr 29, 4:59PM EDT
    ProfileGet Profile for:
    MannKind Corp.
    28903 North Avenue Paine
    Valencia, CA 91355
    United States - Map
    Phone: 661-775-5300
    Website: http://www.mannkindcorp.com

    Index Membership:N/A
    Full Time Employees:287

    Business Summary 

    MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MannKind Corp.

    Corporate Governance 
    MannKind Corp.’s ISS Governance QuickScore as of Apr 1, 2016 is 6. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 3; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Matthew J. Pfeffer CPA, 58
    Chief Exec. Officer and Chief Financial Officer
    Mr. Alfred E. Mann , 90
    Founder and Chairman Emeritus
    Mr. Joseph Kocinsky , 52
    Chief Technology Officer and Corp. VP
    Dr. David B. Thomson Ph.D., J.D., 49
    Corp. VP, Gen. Counsel and Corp. Sec.
    Ms. Rosabel Realica Alinaya ,
    Principal Accounting Officer and Sr. VP of Fin.
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders